医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
31期
63-64
,共2页
依达拉奉%脑梗死%疗效
依達拉奉%腦梗死%療效
의체랍봉%뇌경사%료효
Edaravone%Cerebral infarction%Ef icacy
目的观察依达拉奉治疗急性脑梗死的疗效。方法急性脑梗死120例随机分为治疗组(依达拉奉加常规治疗)，对照组(常规治疗)两组，治疗组60例，对照组60例。观察治疗后神经功能改善情况并进行疗效评定。结果治疗组治疗后各时期ESS及ADL评分均显著高于对照组(<0.05)，14d、21d及30d的ESS及ADL评分显著高于对照组(<0.05)。结论依达拉奉能显著提高急性脑梗死的疗效。
目的觀察依達拉奉治療急性腦梗死的療效。方法急性腦梗死120例隨機分為治療組(依達拉奉加常規治療)，對照組(常規治療)兩組，治療組60例，對照組60例。觀察治療後神經功能改善情況併進行療效評定。結果治療組治療後各時期ESS及ADL評分均顯著高于對照組(<0.05)，14d、21d及30d的ESS及ADL評分顯著高于對照組(<0.05)。結論依達拉奉能顯著提高急性腦梗死的療效。
목적관찰의체랍봉치료급성뇌경사적료효。방법급성뇌경사120례수궤분위치료조(의체랍봉가상규치료)，대조조(상규치료)량조，치료조60례，대조조60례。관찰치료후신경공능개선정황병진행료효평정。결과치료조치료후각시기ESS급ADL평분균현저고우대조조(<0.05)，14d、21d급30d적ESS급ADL평분현저고우대조조(<0.05)。결론의체랍봉능현저제고급성뇌경사적료효。
Objective To evaluate the ef icacy and safety of edaravone in treatment of acute cerebral infarction. Methods 120 patients with acute cerebral infarction were randomly divided into edaravone group (62case)and control group(60case). Results The ESS and Barthel ADL index scores in treatment group were improved significantly than that in the control group ( <0.05),there was asignificant dif erence between treament group and control group. Conclusion Edaravone in treatment of cerebral infarction can be more ef ective to reduction at the 14 th、21 th and 30 th after theatment of the neurological deficit than control group.
